| Autor: |
Jacobsen EJ; Departments of Structural, Analytical and Medicinal Chemistry, Central Nervous System Diseases Research, Computer Aided Drug Discovery, and Pharmacokinetics and Bioanalysis Research, Upjohn Laboratories, Kalamazoo, Michigan 49001, USA., Stelzer LS, TenBrink RE, Belonga KL, Carter DB, Im HK, Im WB, Sethy VH, Tang AH, VonVoigtlander PF, Petke JD, Zhong WZ, Mickelson JW |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of medicinal chemistry [J Med Chem] 1999 Apr 08; Vol. 42 (7), pp. 1123-44. |
| DOI: |
10.1021/jm9801307 |
| Abstrakt: |
A series of imidazo[1,5-a]quinoxaline piperazine ureas appended with a tert-butyl ester side chain at the 3-position was developed. Analogues within this series have high affinity for the gamma-aminobutyric acid A (GABAA)/benzodiazepine receptor complex with efficacies ranging from inverse agonists to full agonists. Many analogues were found to be partial agonists as indicated by [35S]TBPS and Cl- current ratios. Uniquely, a number of these analogues were found to have a bell-shaped dose-response profile in the alpha1 beta2 gamma2 subtype as determined by whole cell patch-clamp technique, where in vitro efficacy was found to decrease with increasing drug concentration. Many of the compounds from this series were effective in antagonizing metrazole-induced seizures, consistent with anticonvulsant and possibly anxiolytic activity. Additionally, several analogues were also effective in lowering cGMP levels (to control values) after applied stress, also consistent with anxiolytic-like properties. The most effective compounds in these screens were also active in animal models of anxiety such as the Vogel and Geller assays. The use of the piperazine substituent allowed for excellent drug levels and a long duration of action in the central nervous system for many of the quinoxalines, as determined by ex vivo assay. Pharmacokinetic analysis of several compounds indicated excellent oral bioavailability and a reasonable half-life in rats. From this series emerged two partial agonists (55, 91) which had good activity in anxiolytic models, acceptable pharmacokinetics, and minimal benzodiazepine-type side effects. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
